Close Menu

BioMérieux

A handful of recently published trials suggest that use of the pneumonia panel could lead to more targeted therapy delivered more quickly than standard methods.

The test is validated and authorized for numerous extraction technologies and PCR instruments.

The panel is designed to detect and differentiate between nucleic acids from SARS-CoV-2 and 20 other viral and bacterial respiratory pathogens.

First quarter revenue growth was driven by "unprecedented demand" for molecular biology products for use in COVID-19 testing.

The 45-minute test was developed by BioMérieux subsidiary BioFire Defense and can be used on the company's FilmArray and FilmArray Torch systems.

Test makers are preparing to ramp up production of new SARS-CoV-2 assays and designated testing systems in anticipation of increased demand.

The Economist writes that two kinds of testing are important to control the spread of COVID-19.

BioMérieux had alleged infringement of two of its patents associated with nucleotide sequences to detect HIV-1 subtypes. 

Technology partners on the study include BioMérieux and SkylineDx, as well as Imperial College London's biomedical electronics unit.

In the quarter, the firm entered a partnership with Specific Diagnostics and also submitted an enhanced version of its blood culture ID panel for regulatory clearance.

Pages

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.